BRIEF: Sichuan Biokin launches Hong Kong IPO, eyes Stock Connect program entry
Biopharmaceutical company Sichuan Biokin Pharmaceutical (2615.HK; 688506.SH) launched its Hong Kong IPO on Friday, aiming to raise up to HK$3.36 billion ($432 million) by selling 8.63 million shares for between…
FAST NEWS: WuXi XDC’s profit surges on growth in ADC market
The latest: WuXi XDC Cayman Inc. (2268.HK) announced Thursday that it expects to report its net profit last year jumped more than 80% from 2022, while its adjusted net profit and…
WuXi Biologics hatches new baby with ADC drug unit IPO
The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs Key Takeaways: WuXi XDC has…
Investors Bet Big on Cancer Drug Infant Duality Biologics and Its Rockstar Founder
Company has raised $120 million in 18 months from A-list investors including Eli Lilly and domestic heavyweight WuXi Biologics Key takeaways Duality Biologics’ new $90 million funding just 18 months…
Recent Articles
RELATED ARTICLES
-
Sichuan Teway spices up Hong Kong’s hot IPO market
603317.SHG -
Unisound launches modest IPO into crowded Hong Kong market
9678.HK
-
Helmed by new chairman, Best Mart 360 navigates changing Hong Kong landscape
2360.HK
- Intsig scans global financial markets for cash with Hong Kong IPO
-
BRIEF: Zenergy included in program making its stock available to Mainland China investors
3677.HK
-
Fibocom limps out of IPO gate, weighed down by sagging margins
0638.HK 300638.SHE
-
JD.com sets up Hong Kong bridgehead as real-time retail battle moves overseas
9618.HK JD.US
